Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMPIONS: SB-913 in MPS II
NCT03041324Phase 2Terminated
- Sponsor
- Sangamo Therapeutics
- Start
- May 2017
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of tefidsogene civaparvovec in mucopolysaccharidosis type 2, sponsored by Sangamo Therapeutics. Primary endpoint: Number of Treatment-Emergent Adverse Events and Serious Adverse Events at 36 months. Started May 2017; status: terminated.
02
Drugs
tefidsogene civaparvovec
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NCT03041324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041324.